(Q37834033)

24 August 2017

1 reference

title

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? (English)

1 reference

24 August 2017

1 reference

1 reference

atherogenic dyslipidemia

1 reference

based on heuristic

inferred from title

author

Dimitri P Mikhailidis

5

object named as

Dimitri P Mikhailidis

1 reference

24 August 2017

Egle Corrado

2

1 reference

ORCID Public Data File 2021

author name string

Manfredi Rizzo

1

1 reference

24 August 2017

Angelo Maria Patti

3

1 reference

24 August 2017

Giovam Battista Rini

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

2 February 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

647-655

1 reference

The role of cilostazol in the treatment of intermittent claudication

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Coronary stent restenosis in patients treated with cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Lipoprotein(a). A genetic risk factor for premature coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Lipoprotein(a) and ischemic cerebrovascular disease in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Low-density lipoprotein size and cardiovascular risk assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Postprandial lipoprotein metabolism and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Targets for intervention in dyslipidemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Analysis of the cilostazol safety database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.557359

10.1517/14656566.2011.557359

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference